In light of growing evidence of the impact of endocrine treatment on patient quality of life and its toxicities13, potential benefits and risks in this subgroup of patients are usually carefully weighed and a significant number of ER-low positive BC patients do not receive adjuvant endocrine treatment in clinical practice. Here, ESR1 is linked to breast cancer.